Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Primary Non-Human Primate (NHP) Cell Cytotoxicity Assay Service
Are you currently facing challenges in translating preclinical safety data to human clinical trials? Our Primary NHP Cell Cytotoxicity In Vitro Cell-Based Safety Assays help you accelerate your drug development process by providing a biologically relevant and predictive platform for safety evaluation. Through advanced cell-based assays using NHP cells, we enable you to de-risk your pipeline and make more informed decisions earlier.
Understanding the Importance of NHP Cell-Based Safety Assays
NHP cells are invaluable for preclinical safety assessment due to their close genetic and physiological similarity to human cells. This biological relevance makes them a superior model for predicting human-specific responses to therapeutic compounds, especially for novel biologics and gene therapies. By using NHP cells in in vitro assays, researchers can gain insights that are difficult or impossible to obtain from rodent models alone.
What Our Service Is
Our comprehensive service offerings provide a robust platform for evaluating drug safety and mechanism of action. We provide detailed analysis across a range of critical assays.
- Screening New Drug Candidates: The services can be used to test potential new drugs early in the development process to see if they are toxic to cells. This helps researchers quickly identify and discard compounds that are likely to be unsafe, saving time and money.
- Investigating Drug-Drug Interactions: As seen in the analysis of the gene therapy article, these cell-based assays can be used to understand why a drug might cause an unexpected reaction in a patient by revealing the underlying biological mechanisms, such as a drug suppressing gene expression.
Why Choose Us?
Creative Biolabs creates significant value by addressing key pain points in preclinical development:
- Pain Point: Low Translational Success: The biological relevance of our NHP models provides data that is highly predictive of human outcomes, reducing the risk of clinical trial failure.
- Pain Point: Time & Cost: Our efficient in vitro assays provide rapid and cost-effective screening, allowing you to quickly identify and advance the most promising drug candidates.
Distributed under Unsplash License, from Unsplash.
Key Benefits of Our Service
Choosing Creative Biolabs for your preclinical safety studies offers a distinct advantage in a competitive landscape. Our services are built on a foundation of scientific excellence and operational efficiency, ensuring you receive the highest quality data to support your project. Published data confirms that in vitro hepatocyte models, particularly those from NHPs, provide accurate and predictive results for gene therapy safety and efficacy.
- Response Speed: We understand the urgency of drug development. Our streamlined processes ensure rapid turnaround times for critical data, keeping your project on schedule.
- High-Quality NHP Resources: We utilize a reliable supply of ethically sourced primary NHP cells, which includes but not limited to hepatocytes, PBMCs, multiple immune cells, guaranteeing consistency and quality across all your studies.
- Customization: We offer flexible assay formats that can be tailored to the specific needs of your therapeutic compound and project goals, from simple cytotoxicity screening to complex mechanism-of-action studies.
- Reporting Depth: Our comprehensive final reports go beyond raw data, providing detailed analysis, expert interpretation, and actionable insights to guide your decision-making process.
How Creative Biolabs' Safety Assays Can Assist Your Project?
Our Primary NHP Cell Cytotoxicity service provides a clear, reliable, and scientifically rigorous path for evaluating the safety of your drug candidates. We provide a solution that is grounded in reality, offering clear deliverables and transparent processes to help you solve key problems in your project development.
01
Required Starting Materials
02
Project Scoping and Design
03
Cell Culture and Plating
04
Compound Treatment
05
Assay Incubation and Readout
06
Data Analysis and Reporting
Key Deliverables
Upon completion of your project, you will receive a comprehensive package of deliverables, including:
- Detailed Lab Report: A written report with a summary of the methodology, a description of the results, and a scientific interpretation of the findings.
- Raw Data: The complete, unprocessed data files from the assays.
- Model Annotations: Detailed information on the specific NHP cells used, including their source, passage number, and any relevant culture conditions.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: How do your NHP cell-based assays compare to traditional animal models for safety testing?
A: While animal models remain important, our NHP cell-based assays offer a more predictive platform for human safety. They are more biologically relevant than rodent models and are a cost-effective way to de-risk your pipeline earlier in the development process, saving you time and resources.
Q: Can you customize the assays to fit my specific drug and project?
A: Absolutely. Our assays are highly flexible. We can work with you to customize the cell type, assay format, and data analysis to meet the unique needs of your therapeutic and project goals.
Q: What type of data will I receive from your service?
A: You will receive a comprehensive lab report that includes raw data, a summary of the methodology, and expert analysis. Our reports provide a clear interpretation of the results to help guide your decision-making.
Q: Is your service suitable for all types of therapeutics?
A: Our assays are particularly well-suited for biologics, such as antibodies and gene therapies, where species differences can be significant. We can discuss your specific therapeutic to determine the best approach.
Q: What kind of information do I need to provide to get started?
A: To get started, you'll need to provide us with your compound and some basic information about your project. We'll then work with you to design a study that meets your needs.
Contact Us
At Creative Biolabs, we are committed to providing innovative solutions that accelerate your drug development and enhance the safety of your therapeutic pipeline. Our Primary NHP Cell Cytotoxicity In Vitro Cell-Based Safety Assays offer a reliable, efficient, and predictive platform to support your research.